Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 8/17 cls
Acusphere (ACUS) Susquehanna Angela Larson Downgrade Neutral (from net positive) -5% $1.62
Larson noted that an NDA submission and subsequent approval of Imagify gas-filled polymer microsphere ultrasound contrast agent could take more than 18 months, based on a lack of clarity on "accuracy" as an FDA-validated clinical endpoint (see BioCentury, May 7).
Aeterna Zentaris (TSX:AEZ; AEZS) Dundee David Martin Rating change Speculative buy -4% $2.51
Martin changed his rating to "speculative buy" from "under review." He believes there is "relatively low risk" that trials conducted by Solvay

Read the full 1049 word article

How to gain access

Continue reading with a
two-week free trial.